# Vir Biotechnology, Inc.: overview

VIR · Nasdaq · CIK 1706431 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vir.md) · [Financials](/companies/vir/financials.md) · [Filings](/companies/vir/filings.md) · [Insiders](/companies/vir/insiders.md)

Latest reported revenue: [$238.9m](/filings/0001628280-26-053549.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-053549).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.4](/filings/0001628280-25-049694.md) | [12.4 d](/filings/0001628280-26-010749.md) | [3.0](/filings/0001628280-25-023291.md) | [1.2](/filings/0001628280-25-038431.md) | [0.2](/filings/0001628280-25-049694.md) | [64.1 d](/filings/0001628280-26-010749.md) | [(0.0)](/filings/0001628280-26-031471.md) | [239](/filings/0001628280-26-053549.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(9718.7%)](/filings/0001628280-25-049694.md) | [(946.7%) d](/filings/0001628280-26-010749.md) | [(4602.5%)](/filings/0001628280-26-031471.md) | [(9754.3%)](/filings/0001628280-26-053549.md) | [(72267.9%)](/filings/0001628280-25-049694.md) | [(74.8%) d](/filings/0001628280-26-010749.md) | [456172.4%](/filings/0001628280-26-031471.md) | [30.7%](/filings/0001628280-26-053549.md) |
| Net margin | % | [(8979.7%)](/filings/0001628280-25-049694.md) | [(845.2%) d](/filings/0001628280-26-010749.md) | [(3989.6%)](/filings/0001628280-26-031471.md) | [(9139.9%)](/filings/0001628280-26-053549.md) | [(67975.4%)](/filings/0001628280-25-049694.md) | [(67.0%) d](/filings/0001628280-26-010749.md) | [433431.0%](/filings/0001628280-26-031471.md) | [33.5%](/filings/0001628280-26-053549.md) |
| Diluted EPS | $ per share | [(1.56)](/filings/0001628280-25-049694.md) | not reported | [(0.88)](/filings/0001628280-26-031471.md) | [(0.80)](/filings/0001628280-26-053549.md) | [(1.17)](/filings/0001628280-25-049694.md) | not reported | [(0.85)](/filings/0001628280-26-031471.md) | [0.47](/filings/0001628280-26-053549.md) |
| Free cash flow | $m | [(174) d](/filings/0001628280-25-049694.md) | [(89.6) d](/filings/0001628280-26-010749.md) | [(79.7)](/filings/0001628280-26-031471.md) | [(123) d](/filings/0001628280-26-053549.md) | [(168) d](/filings/0001628280-25-049694.md) | [(26.2) d](/filings/0001628280-26-010749.md) | [(133)](/filings/0001628280-26-031471.md) | [123 d](/filings/0001628280-26-053549.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,095](/filings/0001628280-24-006852.md) | [1,616](/filings/0001628280-25-008245.md) | [86.2](/filings/0001628280-26-010749.md) | [74.2](/filings/0001628280-26-010749.md) | [68.6](/filings/0001628280-26-010749.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [38.4%](/filings/0001628280-24-006852.md) | [51.6%](/filings/0001628280-25-008245.md) | [(794.0%)](/filings/0001628280-26-010749.md) | [(791.3%)](/filings/0001628280-26-010749.md) | [(699.2%)](/filings/0001628280-26-010749.md) |
| Net margin | % | [48.3%](/filings/0001628280-24-006852.md) | [31.9%](/filings/0001628280-25-008245.md) | [(713.7%)](/filings/0001628280-26-010749.md) | [(703.4%)](/filings/0001628280-26-010749.md) | [(638.9%)](/filings/0001628280-26-010749.md) |
| Diluted EPS | $ per share | [3.96](/filings/0001628280-24-006852.md) | [3.83](/filings/0001628280-25-008245.md) | [(4.59)](/filings/0001628280-26-010749.md) | [(3.83)](/filings/0001628280-26-010749.md) | [(3.16)](/filings/0001628280-26-010749.md) |
| Free cash flow | $m | [(69.4)](/filings/0001628280-24-006852.md) | [1,595](/filings/0001628280-25-008245.md) | [(800)](/filings/0001628280-26-010749.md) | [(454)](/filings/0001628280-26-010749.md) | [(397)](/filings/0001628280-26-010749.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vir/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $210.7m | 20,678,283 |  | Added +2,679,954 |
| [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $129.4m | 12,694,163 |  | Reduced −222,500 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $117.1m | 11,495,215 |  | Added +2,279,638 |
| [SB INVESTMENT ADVISERS (UK) LTD](/funds/1731509.md) | 2026-06-30 | $111.6m | 10,948,093 |  | Unchanged |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $101.5m | 9,964,151 |  | Added +2,823,057 |
| [GSK plc](/funds/1131399.md) | 2026-06-30 | $87.1m | 8,550,954 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $65.1m | 6,388,775 |  | Added +1,006,672 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $57.7m | 5,666,821 |  | Added +3,714,587 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $34.1m | 3,348,366 |  | Added +690,523 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $31.8m | 3,119,421 |  | Added +539,743 |

## Recent filings

[All 787 filings](/companies/vir/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 08:37 ET | [8-K](/filings/0001628280-26-067742.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-067742 |
| 2026-10-14 | 08:35 ET | [8-K](/filings/0001628280-26-065826.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-065826 |
| 2026-10-08 | 08:38 ET | [8-K](/filings/0001628280-26-065408.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-065408 |
| 2026-10-01 | 08:34 ET | [8-K](/filings/0001628280-26-064117.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-064117 |
| 2026-08-05 | 17:20 ET | [10-Q](/filings/0001628280-26-053549.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053549 |
| 2026-08-05 | 16:09 ET | [8-K](/filings/0001628280-26-053351.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053351 |
| 2026-07-24 | 08:31 ET | [8-K](/filings/0001628280-26-049499.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-049499 |
| 2026-06-10 | 16:27 ET | [8-K](/filings/0001628280-26-042237.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-042237 |
| 2026-05-28 | 09:01 ET | [8-K](/filings/0001628280-26-038630.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001628280-26-038630 |
| 2026-05-07 | 17:32 ET | [10-Q](/filings/0001628280-26-031471.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031471 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-010749.md), filed Feb 23, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/53f95d92-21fe-41a6-9ac8-a323fdb2f210)

## About the filer

- CIK: 1706431
- Tickers: VIR
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 08:38 ET. No prices; not investment advice.